Mon.Feb 05, 2024

article thumbnail

‘Where you live shouldn’t determine how you get cancer’: An oncologist on global disparities

STAT

The prediction is dire: Cancer cases around the world are expected to surge 77% by 2050, a new report from the World Health Organization estimates. That attention-grabbing statistic, based on an analysis of 185 countries, cites a growing, aging population and factors including tobacco, alcohol, obesity, and pollution. Perhaps the most damning part of the report reveals the disparities determined by income.

363
363
article thumbnail

ALiEM AIR Series | Toxicology Module

ALiEM - Pharm Pearls

Welcome to the AIR Toxicology Module! After carefully reviewing all relevant posts in the past 12 months from the top 50 sites of the Digital Impact Factor [1], the ALiEM AIR Team is proud to present the highest quality online content related to related to toxicology in the Emergency Department. 8 blog posts met our standard of online excellence and were approved for residency training by the AIR Series Board.

215
215
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medical devices with screens aren’t accessible to the blind. Congress has chance to change that

STAT

Katie Keim was diagnosed with type 1 diabetes in 1967 when she was eight, well before the era of insulin pumps or even reliable home testing. The condition started eating away at her vision 20 years later. By the time she was 36, her sight was completely gone.  Keim had lived an independent life as a child despite her illness. Her summers were spent exploring oceans with her family, not at diabetic summer camps.

Diabetes 356
article thumbnail

ASBM Releases Fact Sheet on Emerging Challenges to Interchangeable Biosimilars Policy

Safe Biologics

On January 31st, ASBM released a fact sheet describing a variety of proposed policy changes at the state and federal level which would weaken the interchangeable biosimilar standard, or circumvent the patient protections it provides. These include new bills and regulations at the federal level, as well as state legislation and proposals which threaten to undermine the hard-won gains of the patient and physician communities to ensure that only interchangeable biosimilars are substituted without p

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Texas Medicaid agrees to fully cover gene therapy for Afghan refugees’ infant

STAT

After a months-long fight with Texas Medicaid over coverage of a gene therapy, Afghan refugees now have a chance to save their infant son. After initially balking , Texas officials have agreed to pay for the costly treatment, the boy’s family and his doctor told STAT. At the end of last week, N. Pashai’s cell phone rang. It was from a Minnesota area code.

Hospitals 355
article thumbnail

Vaxxinity is brewing up meds for a spacefaring future

PharmaVoice

The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.

163
163

More Trending

article thumbnail

J&J says top drug prospect works across autoimmune disorders

BioPharma Dive

The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.

124
124
article thumbnail

STAT+: Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production

STAT

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.   Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.

Diabetes 355
article thumbnail

Government hits patent thickets on multiple fronts

PharmaVoice

Patent thickets are the latest target in lawmakers' bid to lower drug prices.

article thumbnail

Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down

STAT

Amgen is trying a unique strategy with its obesity drug candidate: testing whether it can wean patients toward lower or less frequent doses over time. Very early data hints that Amgen’s candidate, called MariTide, may provide longer-lasting weight loss than highly popular obesity drugs on the market like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

362
362
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Data science in healthcare

pharmaphorum

Data science in healthcare is transforming the industry, from drug discovery to patient care. Learn about the role of data, artificial intelligence (AI), and the impact of initiatives like the NHS Datastore in revolutionising healthcare outcomes.

124
124
article thumbnail

STAT+: A sweeping new lawsuit against J&J asks: Are employers liable if they overpay for drugs?

STAT

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers. Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations.

article thumbnail

Novo Holdings to buy contract drugmaker Catalent for $16.5B

BioPharma Dive

In a related deal, Novo Holdings subsidiary Novo Nordisk will buy three major Catalent factories for $11 billion as it works to keep pace with demand for its obesity and diabetes medicines.

Diabetes 111
article thumbnail

STAT+: New Medicare Advantage rule is boon for providers, drag on insurers

STAT

Starting this year, private Medicare plans have to cover their members’ hospitalizations at the higher inpatient rate if their doctors predict they’ll have to stay beyond two midnights. It’s the same rule — appropriately called the two-midnight rule — that traditional Medicare has followed for a decade. After it came out that Medicare Advantage plans were routinely denying coverage for necessary services , the federal government decided they ought to be held to

Hospitals 319
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Study reveals AI can predict patients’ survival in glioblastoma

Pharma Times

The aggressive brain cancer is responsible for over 3,000 cases in the UK every year

149
149
article thumbnail

STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?

STAT

Sixteen billion dollars is a lot of money. But Monday’s announcement that the parent company of Novo Nordisk, the maker of the weight loss drug Wegovy, plans to buy Catalent , a company to which drugmakers outsource manufacturing, is probably even more important than it seems. The deal, done in part so that Novo can rapidly ramp up its ability to manufacture Wegovy, is a massive statement of optimism about the sales potential of that medication and weight loss drugs like it, known as GLP-

Vaccines 327
article thumbnail

Pharmacists report rise in patients unable to collect prescriptions due to cost

The Pharmacist

The last 12 months have seen a marked increase in patients declining prescription medication because of cost, according to new research. The findings have subsequently sparked fresh calls for prescription charges to be reviewed or abolished. A survey of 1,357 pharmacists in England found that 97% had encountered patients foregoing some of the medicines on […] The post Pharmacists report rise in patients unable to collect prescriptions due to cost appeared first on The Pharmacist.

107
107
article thumbnail

STAT+: Devoted Health’s losses in Medicare Advantage persist

STAT

Devoted Health has been one of the most prominent health insurance and provider startups of the past decade — founded and overseen by several alumni of former President Barack Obama’s administration. But it has not turned a profit after five years of selling Medicare Advantage plans to older adults, according to a STAT analysis of Devoted’s financial filings.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Covid-19 vaccine contract extensions to carry added spring payment

The Pharmacist

Pharmacies currently providing the Covid-19 vaccine are being asked by NHS England (NHSE) to extend their service provision contracts until 31 August 2024. The extension covers a potential spring booster programme, with the Joint Committee on Vaccination and Immunisation (JCVI) set to publish their guidance soon. While the fee for the extension period remains at […] The post Covid-19 vaccine contract extensions to carry added spring payment appeared first on The Pharmacist.

Vaccines 105
article thumbnail

STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion

STAT

Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline of cancer drugs for 2.7 billion euros, or $2.9 billion. The Swiss drugmaker will pay 68 euros, or around $73, per share, nearly twice Morphosys’s average trading price over the last month. At the center of the deal is pelabresib, a blood cancer pill that in November posted mixed results in a Phase 3 trial.

282
282
article thumbnail

Astellas raises Padcev forecasts on bladder cancer data

pharmaphorum

A bladder cancer study prompts Astellas to lift peak sales prediction for Padcev, although its menopause therapy Veozah isn’t ramping up as hoped.

115
115
article thumbnail

STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of phone calls, online meetings, and deadlines has predictably returned. But you knew this would happen. After all, the world keeps spinning, at least for now. So time to give it a nudge in a better direction with a cup of delicious stimulation.

Diabetes 264
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

SGD Pharma introduces new range of Type I tubular vials

Express Pharma

SGD Pharma has launched its new range of Type I injectable vials in tubular glass with the added external low-friction coating developed by Corning thanks to an exclusive co-development partnership. A company statement informed, “SGD Pharma’s new Velocity Vial offering reduces the frictional resistance created by glass-to-glass and glass-to-metal contact, helping pharma filing lines to prevent potential disruptions to the flow of vials, which can include tip-overs, jams and glass breakages.

Packaging 110
article thumbnail

STAT+: Diabetes treatments have improperly listed patents that should be removed, analysis finds

STAT

More than half of the injector-pen patents for several widely used diabetes treatments — including Ozempic and Mounjaro — do not mention several important characteristics that should otherwise prevent them from being listed in a key federal registry, according to a new analysis. As a result, the researchers contend the patents may be unfairly used to preclude competition from companies that may want to market lower-cost generic products.

Diabetes 245
article thumbnail

With half of alcoholics refusing to abstain, Kinnov's new drug to fight addiction couldn't come soon enough

Outsourcing Pharma

No new treatments to combat the major public health issue of alcohol use disorder (AUD), have been brought to market for ten years - and with half of heavy drinkers refusing the abstinence route, new drug could be the answer.

103
103
article thumbnail

Regeneron is interested in obesity treatments that combat muscle loss

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Today, we talk about two players that want to join the obesity market with updates to the GLP-1 class: Amgen and Regeneron. Also, a draft bill in Congress would restrict U.S. involvement with Chinese biotechs.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

AbbVie’s new drugs keep post-Humira prospects on track

pharmaphorum

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

104
104
article thumbnail

Novo Nordisk $11b acquisition to support manufacturing capacity

European Pharmaceutical Review

Novo Nordisk is set to acquire three fill-finish manufacturing sites from Novo Holdings A/S (Novo Holdings) for $11 billion. This agreement is part of a transaction in which Novo Holdings agreed to acquire the contract development and manufacturing organisation (CDMO) Catalent. The three manufacturing sites in Anagni in Italy, Brussels in Belgium and in Bloomington, Indiana in the US, specialise in the sterile filling of drugs.

article thumbnail

US FDA gives record number of review designations to CRISPR drugs in 2023: GlobalData

Express Pharma

In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made history by gaining the first FDA approval for a CRISPR-based drug, exagamglogene autotemcel (Casgevy) for the treatment of sickle cell disease with vaso-occlusive crisis. This historic achievement coincided with a record number of 14 review designations awarded by the FDA to CRISPR-based therapies in 2023, according to GlobalData.

109
109
article thumbnail

US legislation to benefit small molecule drug innovation

European Pharmaceutical Review

Incentivising small molecule drug innovation According to the Biotechnology Innovation Organization (BIO), the bipartisan Ensuring Pathways to Innovative Cures ( EPIC Act ) passed last week in the US, is a “critical” step for incentivising small molecule drug innovation. Representative Congressman Dr Greg Murphy, alongside Don Davis and Brett Guthrie, introduced the US legislation to fix the “pill penalty”, BIO confirmed.

article thumbnail

More than 15.5 million doses of illegal medicines seized in 2023

The Pharmacist

Illegally traded medicines with a street value of more than £30m were seized by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2023. The seizures were made as part of an international initiative called Operation Pangea and accounted for more than 15.5 million doses. Among the illegally traded medicines were prescription-only anti-anxiety medication, opioids […] The post More than 15.5 million doses of illegal medicines seized in 2023 appeared first on The Pharmacist.

99